Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

elephone replay will be available through November 6, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the trial design, occurrence, timing, and pace of future clinical trials, the timing for obtaining viral load data and expectations regarding such data, as well as the anticipated future clinical benefits of ANA598 and ANA773. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Electronic circuits are based on electrons, but one of ... photonic circuits, i.e. circuits based on light (photons) instead ... to create a stream of single photons and control ... sorts of attempts to achieve this control, but now ... creating a steady stream of photons emitted one at ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/28/2014)... 28, 2014 SPIE Fellow Glenn Boreman, ... Optical Science and Director of the Center for Optoelectronics ... at Charlotte, and co-founder and Chairman of the Board ... the 2015 Vice President of SPIE, the international society ... Stahl announced recent election results at the Annual General ...
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... China, Jan. 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech ... acquisition of AppTec Laboratory,Services, Inc., a US-based ... industries. AppTec offers testing, contract research and,development, ... highly,differentiated, fully integrated platform., (Logo: ...
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting at ... in New York on,Wednesday, February 6, 2008 at 1:00 ... Vice President, Finance and Chief Financial Officer of,Amylin Pharmaceuticals, ... presentation and breakout session will be webcast, and a,recording ...
... International,Inc. (Nasdaq: CHDX ) a leading independent ... the People,s Republic of China,announced that it intends ... ended December 31, 2007, on Friday, February 8, ... conference call on Friday,February 8, 2008 at 10:00 ...
Cached Biology Technology:WuXi PharmaTech Completes Acquisition of AppTec 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008 2Chindex International Announces Conference Call to Discuss Its Fiscal 2008 Third Quarter Results on Friday, February 8, 2008 3
(Date:8/28/2014)... -- Privacy Advocate and Senior Staff Attorney at the Electronic ... lineup of biometric and mobile commerce experts set to ... in Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and Philippe ... of this year,s event is Mobility at the Crossroads ...
(Date:8/28/2014)... Aug. 28, 2014A new method for measuring and imaging ... doctors and researchers better understand how drug abuse affects ... and tissue engineering, and lead to better treatment options ... a team of researchers from Stony Brook University in ... Health, was published today in The Optical Society,s (OSA) ...
(Date:8/28/2014)... health risk to people with asthma according to a new ... Immunology . , By critically reviewing the findings from 17 ... the presence of several types of mould can lead to ... likelihood of developing the condition. , The research has been ... School and is the first time all of the information ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Indoor mold poses health risk to asthma sufferers 2
... NY, September 4, 2012The use of RNA in nanotechnology ... development of new therapeutic compounds. Key technical challenges remain, ... use of RNA molecules in nanotechnology approaches are presented ... , a peer-reviewed journal from Mary Ann Liebert, ...
... appliances in Spain are processed out of the Integrated ... of Salamanca exposes how many manufacturers are not registered ... According to the European directive on waste electrical ... the waste they generate during their activity until reaching ...
... fungal species, called , Hebelomagriseopruinatum , has now officially ... whose name can be translated into ,the grey-dewy tear ... mushroom-hunting tour headed by postdoc Jacob Heilman-Clausen from the ... 2009, postdoc Jacob Heilman-Clausen from the Center for Macroecology, ...
Cached Biology News:More than 70% of electronic waste management is uncontrolled 2More than 70% of electronic waste management is uncontrolled 3New Danish fungal species discovered 2
Request Info...
...
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: